50% offfirst month · 3+ month plans
Patient portalFind my treatment
PT-141 needle-free formats arranged in warm rose light
All treatments

Rebody treatment guide

Bremelanotide (PT-141) Formats for Low Desire

The nasal bottle is the simplest PT-141 format. Choose a troche when nasal delivery is the obstacle.

Choose the nasal spray when fast physical administration matters. Choose a troche when nasal use is the deal-breaker. Rebody's PT-141 family includes two nasal concentrations and two mini-troche strengths, all refrigerated. Route convenience is clear; clinical superiority is not.

The short answer

PT-141 is another name used for bremelanotide, a melanocortin-receptor agonist developed around sexual desire and arousal. FDA-approved Vyleesi contains bremelanotide as a 1.75 mg subcutaneous injection for acquired, generalized hypoactive sexual desire disorder in premenopausal women.

Rebody's nasal sprays and troches are different finished products and routes. The spray bottle wins on simple administration. Troches avoid the nose and pump. Neither should promise the results, onset, or dose of the approved injection.

Available formats at a glance

Format Strengths Package Storage Final dose instructions
Nasal spray 5 mg/mL and 10 mg/mL 5 mL bottle Refrigerated Patient-specific prescription
Mini troche 1 mg and 2 mg 10 troches Refrigerated Patient-specific prescription

The 5 mg/mL presentation is not available in California. Your prescription and dispensing label provide the pump output, sprays per use, priming, troche placement, timing, package duration, and refill cadence.

PT-141, bremelanotide, and Vyleesi

PT-141 is the development name commonly used for bremelanotide. Vyleesi is a specific FDA-approved bremelanotide injection with its own autoinjector, label, indication, dose, pharmacokinetics, and safety information.

A compounded nasal bottle or troche is not generic Vyleesi. It changes route, formulation, package, and exposure. Product pages should use bremelanotide to explain active identity while keeping the branded injection separate.

This distinction prevents two common errors: calling any PT-141 product FDA-approved and quoting the injection's human outcomes as proof for a spray or troche.

What bremelanotide does

Bremelanotide activates melanocortin receptors in the central nervous system. Its sexual-health research centers on desire and distress rather than simply increasing genital blood flow.

That makes it different from sildenafil and tadalafil, which act through the nitric-oxide/cGMP blood-flow pathway used in erectile function. Desire and erection can interact, but they are not the same problem.

Do not sell PT-141 as a guaranteed orgasm, automatic erection, lubricant, relationship treatment, or hormone replacement. The strongest evidence is narrower and more useful: premenopausal women with acquired, generalized HSDD using the approved injection.

What the injection trials measured

The two RECONNECT phase 3 trials randomized 1,267 premenopausal women with acquired, generalized HSDD. Participants used 1.75 mg subcutaneous bremelanotide as needed for 24 weeks.

The co-primary outcomes measured sexual desire and distress related to low desire. Bremelanotide improved both versus placebo. The number of satisfying sexual events did not improve significantly as a co-primary efficacy result.

That study population and route define the evidence. It is strong support for bremelanotide as a desire medication in that population, not a route conversion for Rebody's needle-free products.

What intranasal studies measured

A small double-blind crossover experiment studied one 20 mg intranasal dose in 18 premenopausal women with female sexual arousal disorder. It explored physiological and subjective arousal measures. It did not test either Rebody concentration or establish a retail pump dose.

Early intranasal research also included healthy men and men with mild-to-moderate erectile dysfunction. These small studies examined pharmacology and erectile response, not a modern pivotal indication or the finished 5 mL bottle.

Intranasal research therefore makes the route scientifically real. It does not authorize a precise onset claim, outcome percentage, or sprays-per-dose instruction.

Why the nasal bottle wins on simplicity

A metered spray can be administered in seconds and does not require waiting for a solid to dissolve. The 5 mL bottle is compact and familiar. For someone comfortable with nasal products, those are decisive practical advantages.

The dispensing label provides pump output, amount per actuation, priming, nostril technique, timing, and maximum frequency. Concentration alone cannot answer “how many sprays.”

Congestion, irritation, leakage, a blocked pump, or dislike of nasal sensation can erase the convenience. That is where troche becomes the better practical form.

Why troches remain a real alternative

The mini troche dissolves under the tongue or between gum and cheek. It avoids nasal administration and pump technique. Each package contains 10 troches at either 1 mg or 2 mg.

Troche use introduces different questions: dissolve time, saliva, taste, accidental swallowing, food and drink, mouth irritation, and the amount absorbed through mucosa. No route-specific clinical outcome study establishes the Rebody troche.

Choose troche for route preference, not because the lower printed milligram number implies gentler or more precise exposure.

Strengths cannot be converted across routes

Five or ten milligrams per milliliter describes concentration in a bottle. One or two milligrams describes active in one troche. The nasal amount per actuation remains unknown, and troche bioavailability is not established.

Do not convert a Vyleesi 1.75 mg injection into sprays or troches. Subcutaneous bioavailability and systemic exposure are route-specific. The same active name is not a conversion factor.

Only the final prescription can define the strength, amount, timing, and maximum use for each product.

Timing and spontaneity

People search PT-141 because they want an as-needed product that does not turn intimacy into a rigid daily medication schedule. That desire makes timing central.

The approved injection label says use at least 45 minutes before anticipated sexual activity, but that instruction belongs to Vyleesi injection. It cannot be copied onto a nasal bottle or troche. Small studies and online anecdotes report widely varying timing.

Until route-specific instructions are approved, the strong answer is operational: both are prescribed as as-needed formats; exact lead time remains a product-label fact.

Refrigeration and travel

Both formats are refrigerated. Keep the bottle or troche package labeled, protect it from freezing, and follow its temperature-excursion instructions during travel.

The nasal bottle needs leak protection and a cap. Troches need protection from heat, moisture, and physical damage. Do not decant either into an unlabeled travel container.

If a shipment arrives warm, record delivery timing and package condition. If a spray leaks or troches soften, crack, or become wet, check the product before use.

Safety follows the active and the route

The Vyleesi label contraindicates uncontrolled hypertension and known cardiovascular disease. It addresses transient blood-pressure increases, heart-rate reduction, nausea, focal hyperpigmentation, pregnancy, delayed gastric emptying, and reduced exposure to oral naltrexone.

Those injection-label facts define important bremelanotide questions. They do not prove that route-specific frequency or adverse-event rates are identical for a spray or troche.

Seek urgent help for severe allergic symptoms, chest pain, fainting, severe or persistent blood-pressure symptoms, or prolonged painful erection. Follow the route-specific instructions and escalation guidance supplied with the prescription.

Price, supply, and availability

Rebody's 5 mL nasal bottle is $99.50 first month, then $199, and its 10-count troche package is $74.50 first month, then $149. Billable days of supply remain prescription-specific. Ten troches do not automatically equal ten days or one month; a 5 mL bottle does not reveal its number of doses without metered output and prescribed sprays.

Both product families are available: $99.50 first month, then $199 per 5 mL nasal bottle and $74.50 first month, then $149 per 10-count troche package. Strength is prescribed within each route.

Compare package price, expected number of prescribed uses, cold shipping, and refill timing.

Questions people ask

Is PT-141 the same as bremelanotide?

Yes, PT-141 is a common development name for bremelanotide. Vyleesi is the specific approved injection product.

Which needle-free format is fastest?

Nasal administration takes less physical time. A clinical onset winner has not been established for the products.

Does PT-141 work for men?

Small early intranasal studies examined men, but Vyleesi is approved for premenopausal women with acquired, generalized HSDD, not male ED.

How long does it last?

Do not copy the injection or anecdotal timeline onto spray or troche. Final route-specific guidance should answer timing.

Can it be used with Viagra or Cialis?

That combination requires individualized safety instructions. Small research interest does not create a public stacking protocol.

Bottom line

Nasal PT-141 wins the practical route comparison because a spray takes seconds. Troche wins when nasal administration is the problem. Both refrigerated formats are available at the package prices above; patient-specific directions determine timing and supply. Choose the form by physical routine and keep Vyleesi's injection evidence attached to the injection.

Shop the formats and read the route guide

Primary sources